Get started
Author

Inder Bhamra

N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: Indazoles as phenol isosteres with improved pharmacokinetics
2007 · Paul Bamborough, Richard M. Angell, et al. · Bioorganic & Medicinal Chemistry Letters · 50
The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand–dependent Cancer Models
2022 · Caroline Phillips, Inder Bhamra, et al. · Cancer Research Communications · 40
Base-pairing preferences, physicochemical properties and mutational behaviour of the DNA lesion 8-nitroguanine †
2012 · Inder Bhamra, Patricia Compagnone-Post, et al. · Nucleic Acids Research · 23
PDF
Abstract 506: Wnt/â-Catenin pathway inhibitor RXC004 enhances the immunity of pre-clinical models of cancer
2019 · Caroline Phillips, Inder Bhamra, et al. · Cancer Research · 11
α-Lithio quinuclidine N-oxide (Li-QNO): A new base for synthetic chemistry
2006 · Ian A. O'Neil, Inder Bhamra, et al. · Chemical Communications · 11
Novel porcupine (PORCN) inhibitor RXC004: Evaluation in models of RNF43 loss of function cancers.
2017 · Inder Bhamra, Nick Adams, et al. · Journal of Clinical Oncology · 10
Abstract 3764: Porcupine inhibitor RXC004 enhances immune response in pre-clinical models of cancer
2018 · Inder Bhamra, Richard Armer, et al. · Cancer Research · 9
Artemisinin–Polypyrrole Conjugates: Synthesis, DNA Binding Studies and Preliminary Antiproliferative Evaluation
2013 · Louise La Pensée, Sunil Sabbani, et al. · ChemMedChem · 8
Preclinical data using a novel porcupine inhibitor demonstrates that inhibition of porcupine is a promising target for the treatment of Idiopathic Pulmonary Fibrosis
2019 · Peter Bunyard, Inder Bhamra, et al. · European Respiratory Journal · 5
Abstract 3874: Efficacy of the Wnt/Beta-Catenin pathway inhibitor RXC004 in genetically-defined models of cancer
2019 · Simon Woodcock, Inder Bhamra, et al. · Cancer Research · 5
Stabilization of a Bimolecular Triplex by 3′‐S‐Phosphorothiolate Modifications: An NMR and UV Thermal Melting Investigation
2015 · Kathryn Evans, Inder Bhamra, et al. · Chemistry - A European Journal · 3
Abstract 2566: Pre-clinical efficacy of the Wnt pathway inhibitor RXC004 in combination with anti-cancer therapies
2022 · James Kelly, Simon Woodcock, et al. · Cancer Research · 2
Abstract 998: Mechanism of action of RXC004, a Wnt pathway inhibitor, in genetically-defined models of cancer
2021 · Caroline Phillips, Simon Woodcock, et al. · Cancer Research · 2
The synthesis of functionalised peptides using α-lithio quinuclidine N-oxide (Li-QNO)
2009 · Ian A. O’Neil, Inder Bhamra · Tetrahedron Letters · 2
Directed lithiation on the quinuclidine ring system: the synthesis of 2,3-difunctionalised quinuclidines
2008 · Ian A. O’Neil, James Hitchin, et al. · Tetrahedron Letters · 2
Abstract 944: Pre-clinical activity of the Wnt pathway inhibitor RXC004 in combination with MAPK pathway inhibitors in GI cancer models
2024 · Simon A. Woodcock, Dorottya Keppel, et al. · Cancer Research · 1
Identification of an RNF43 mutated gastric cancer patient population with potential sensitivity to porcupine inhibitor RXC004 and development of a complimentary ctDNA liquid biopsy assay for patient screening
2017 · M. Bingham, I. Bhamra, et al. · Annals of Oncology · 1
PDF
Novel Porcupine inhibitor RXC004: Potent efficacy in animal models of cancer through direct tumour targeting and immunomodulatory mechanisms
2016 · I. Bhamra, V. Abet, et al. · European Journal of Cancer · 1
Inside Cover: Artemisinin–Polypyrrole Conjugates: Synthesis, DNA Binding Studies and Preliminary Antiproliferative Evaluation (ChemMedChem 5/2013)
2013 · Louise La Pensée, Sunil Sabbani, et al. · ChemMedChem · 1
PDF
Abstract A101: Novel KRAS inhibitors suppress MAPK pathway signalling and display potent anti-proliferative activity across a broad range of KRAS mutant cell lines
2023 · Inder Bhamra, Helen Mason, et al. · Molecular Cancer Therapeutics
Development of Novel Selective DDR1 Inhibitors with the Potential to Treat CKD
2023 · Nicolas E. Guisot, Daniel J. Wilcock, et al. · Journal of the American Society of Nephrology
Data from The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand–dependent Cancer Models
2023 · Caroline Phillips, Inder Bhamra, et al.
Supplementary Figures 1-7, Table 1 from The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand–dependent Cancer Models
2023 · Caroline Phillips, Inder Bhamra, et al.
Abstract 1654: Pre-clinical activity of the Wnt/Beta-catenin pathway inhibitor RXC004 in models of biliary tract cancer
2023 · Simon A. Woodcock, Dorottya Keppel, et al. · Cancer Research
Data from The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand–dependent Cancer Models
2023 · Caroline Phillips, Inder Bhamra, et al.
Works count: 29
Citation count: 187
H-index: 8
I10-index: 6
Year
Topic
Type